We’re excited to announce the 5th International Inflammatory Breast Cancer (IBC) Conference, July 9-10, at the Long Wharf Marriott in Boston, MA. Executive Director, Ginny Mason RN, will be speaking on "IBC- A Patient's Perspective" on Saturday morning.
"The primary goal of the IBC conference is to bring together scientists and clinicians who are interested in understanding this unique disease, and to foster collaboration,” Mason said. The two-day symposium will offer discussion on recent innovations in the multidisciplinary treatment of inflammatory breast cancer and explore scientific advances in breast cancer that can be applied to the understanding of this disease.
In addition to presentations from experts in the field of breast cancer, interactive panel discussions and question and answer sessions will foster significant collaboration in the study of inflammatory breast cancer. The target audience includes medical oncologists, radiation oncologists, surgical oncologists, physician’s assistants, nurse practitioners, oncology nurses, physicians in training, and advocates."
The IBC conference follows the Breast Cancer: New Horizons, Current Controversies conference hosted by Harvard Medical School at the same location.
For more information click here.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.